Xeris says XP-8121 Phase 3 on track for late-2028 topline
Xeris Biopharma hosted an XP-8121 program overview, saying Phase 3 Cornerstone is on track to initiate by year-end, with topline results expected in late 2028 and potential U.S. approval and launch in 2030.
Xeris Biopharma hosted an XP-8121 Program Overview and said the Phase 3 Cornerstone trial remains on track to begin by year-end, with topline results expected in late 2028 and potential U.S. approval and launch anticipated in 2030. Key highlights: Original SEC filing: Xeris Biopharma Holdings, Inc. [ X…